Literature DB >> 27865369

Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients.

Justin E Swartz1, Ajit J Pothen2, Inge Wegner3, Ernst J Smid4, Karin M A Swart5, Remco de Bree6, Loek P H Leenen7, Wilko Grolman8.   

Abstract

OBJECTIVES: Patients with head and neck cancer (HNC) have a higher risk of malnutrition and sarcopenia, which is associated with adverse clinical outcome. As abdominal CT-imaging is often used to detect sarcopenia, such scans are rarely available in HNC patients, possibly explaining why no studies investigate the effect of sarcopenia in this population. We correlated skeletal muscle mass assessed on head and neck CT-scans with abdominal CT-imaging.
METHODS: Head and neck, and abdominal CT-scans of trauma (n=51) and HNC-patients (n=52) were retrospectively analyzed. On the head and neck CT-scans, the paravertebral and sternocleidomastoid muscles were delineated. On the abdominal CT-scans, all muscles were delineated. Cross-sectional area (CSA) of the muscles at the level of the C3 vertebra was compared to CSA at the L3 level using linear regression. A multivariate linear regression model was established.
RESULTS: HNC-patients had significantly lower muscle CSA than trauma patients (37.9 vs. 45.1cm2, p<0.001, corrected for sex and age). C3 muscle CSA strongly predicted L3 muscle CSA (r=0.785, p<0.001). This correlation was stronger in a multivariate model including sex, age and weight (r=0.891, p<0.001). DISCUSSION: Assessment of skeletal muscle mass on head and neck CT-scans is feasible and may be an alternative to abdominal CT-imaging. This method allows assessment of sarcopenia using routinely performed scans without additional imaging or additional patient burden. Identifying sarcopenic patients may help in treatment selection, or to select HNC patients for physiotherapeutic or nutritional interventions to improve their outcome.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Computed tomography; Computer-assisted image analysis; Head and neck neoplasms; Lean body mass; Sarcopenia

Mesh:

Year:  2016        PMID: 27865369     DOI: 10.1016/j.oraloncology.2016.09.006

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  48 in total

1.  Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial.

Authors:  Julia Furtner; Els Genbrugge; Thierry Gorlia; Martin Bendszus; Martha Nowosielski; Vassilis Golfinopoulos; Michael Weller; Martin J van den Bent; Wolfgang Wick; Matthias Preusser
Journal:  Neuro Oncol       Date:  2019-12-17       Impact factor: 12.300

2.  Comment on "Sarcopenia is a prognostic factor for overall survival in elderly patients with head-and-neck cancer".

Authors:  Vildan Binay Safer; Sibel Eyigör
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-06-06       Impact factor: 2.503

3.  Reply to comment on "Sarcopenia is a prognostic factor for overall survival in elderly patients with head and neck cancer".

Authors:  N Chargi; S I Bril; P A de Jong; M H Emmelot-Vonk; Remco de Bree
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-07-08       Impact factor: 2.503

Review 4.  Imaging of sarcopenia: old evidence and new insights.

Authors:  Domenico Albano; Carmelo Messina; Jacopo Vitale; Luca Maria Sconfienza
Journal:  Eur Radiol       Date:  2019-12-13       Impact factor: 5.315

5.  Masseter muscle parameters can function as an alternative for skeletal muscle mass assessments on cross-sectional imaging at lumbar or cervical vertebral levels.

Authors:  Hugo C van Heusden; Najiba Chargi; Jan Willem Dankbaar; Ernst J Smid; Remco de Bree
Journal:  Quant Imaging Med Surg       Date:  2022-01

6.  Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer.

Authors:  Najiba Chargi; Fereshta Bashiri; Anne W Wendrich; Ernst J Smid; Pim A de Jong; Alwin D R Huitema; Lot A Devriese; Remco de Bree
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-01-17       Impact factor: 2.503

7.  Enhancing evaluation of sarcopenia in patients with non-small cell lung cancer (NSCLC) by assessing skeletal muscle index (SMI) at the first lumbar (L1) level on routine chest computed tomography (CT).

Authors:  Alejandro Recio-Boiles; Jose N Galeas; Bernard Goldwasser; Karla Sanchez; Louise M W Man; Ryan D Gentzler; Jane Gildersleeve; Patricia J Hollen; Richard J Gralla
Journal:  Support Care Cancer       Date:  2018-02-07       Impact factor: 3.603

8.  Skeletal muscle mass at C3 may not be a strong predictor for skeletal muscle mass at L3 in sarcopenic patients with head and neck cancer.

Authors:  Joon-Kee Yoon; Jeon Yeob Jang; Young-Sil An; Su Jin Lee
Journal:  PLoS One       Date:  2021-07-19       Impact factor: 3.240

9.  Exploring definitions of radiological sarcopenia in cancer: a protocol for a scoping review.

Authors:  James Wei Wang; Matthew Williams
Journal:  BMJ Open       Date:  2021-07-02       Impact factor: 2.692

10.  Dysphagia, trismus and speech impairment following radiation-based treatment for advanced stage oropharyngeal carcinoma: a one-year prospective evaluation.

Authors:  Rebecca T Karsten; Najiba Chargi; Lisette van der Molen; Rob J J H van Son; Remco de Bree; Abrahim Al-Mamgani; Jan P de Boer; Frans J M Hilgers; Michiel W M van den Brekel; Ludi E Smeele; Martijn M Stuiver
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-05-27       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.